USSTOCK.TODAY
Weekend. Closed Log in Sign up

Grail anticipates FDA approval and insurer adoption for Galleri test

The Motley Fool +1 · ·by G4L

GRAL
GRAL GRAIL Inc
$99.25 -5.33%
View chart & analysis →
  1. 1Grail's market capitalization volatility of $4.46 billion is likely to continue next year.
  2. 2Grail management expects Galleri, a multi-cancer early detection test, to be approved in Q1 2027.
  3. 3The expected price range for the Galleri test is $500 to $600.

So what's the key point?

Grail's market capitalization volatility of $4.46 billion is likely to continue next year.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →